External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Broad-Based Recovery Supports Earnings Trajectory: Jubilant Ingrevia Ltd. delivered a healthy start to FY27, with all three business segments recording growth during Q1.</li><li>The recovery in Chemical Intermediates provided near-term earnings support, driven by improving demand, better realisations and effective cost pass-through.</li><li>Meanwhile, Specialty Chemicals and Nutrition continued to underpin the company’s structural growth outlook. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Broad-Based Recovery Supports Earnings Trajectory: Jubilant Ingrevia Ltd. delivered a healthy start to FY27, with all three business segments recording growth during Q1.The recovery in Chemical Intermediates provided near-term earnings support, driven by improving demand, better realisations and effective cost pass-through.Meanwhile, Specialty Chemicals and Nutrition continued to underpin the company’s structural growth outlook. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Axis Punch:Jubilant Ingrevia Ltd.  - 24th September, 2026